Eventide Gilead Fund Ranked #1 Midcap Growth Fund by Lipper and the Wall Street Journal for the One-

Eventide Gilead Fund Ranked #1 Midcap Growth Fund by Lipper and the Wall Street Journal for the One-Year Period Ending November 30, 2012

ID: 213820

(firmenpresse) - BOSTON, MA -- (Marketwire) -- 12/18/12 -- The Eventide Gilead Fund (NASDAQ: ETGLX), a mutual fund practicing values-based investing, was named ranked #1 in the Midcap Growth equity category, out of 391 funds, for trailing one-year performance by Lipper and the Wall Street Journal. During this period, the Fund generated a return of 19.52% compared with the Russell Mid-Cap Growth Index return of 12.06%, an out-performance of 7.46%.

The Fund was also named as a "Category King" by the Wall Street Journal for the year-to-date (YTD) period ending November 30, 2012, ranking #8 out of 392 Midcap Growth funds. This marked the third time in 2012 the Gilead Fund has been named Category King by the Wall Street Journal, in recognition of ranking in the top ten funds in its category for performance. This is the ninth Category King award the Fund has garnered since inception.

The following table highlights the Fund's performance over the past four years:





The Eventide Gilead Fund is managed by Eventide Asset Management, LLC, a Boston-based investment advisory firm that is committed to investing in companies that excel at creating value for customers, employees, and society. The Fund was launched on July 8, 2008.

Expenses ratios: Gross Expenses 2.05%; Net Expenses 1.64%. The advisor has agreed to maintain the Fund's total annual operating expenses at 1.64% until at least October 31, 2013. Three-year and inception returns are annualized. The performance data quoted here represents past performance. Current performance may be lower or higher than the performance data quoted above. Past performance is no guarantee of future results. The investment return and principal value of an investment will fluctuate so that investor's shares, when redeemed, may be worth more or less than their original cost. Please review the fund's prospectus for more information regarding the fund's fees and expenses. Performance shown is for No-load Class shares (please see a prospectus for information about other share classes). For performance information current to the most recent month-end, please call toll-free 877-771-EVEN (3836).





Lipper Ratings and Lipper Classifications do not constitute and are not intended to constitute investment advice. As a result, you should not make an investment decision on the basis of this information. Rather, you should use Lipper Ratings and Lipper Classifications for informational purposes only.

The S&P 500 is an index created by Standard & Poor's Corp considered to represent the performance of the stock market generally. The Russell Midcap Growth Index measures the performance of the U.S. equity mid-cap growth segment. It includes mid-cap companies with higher price-to-book ratios and forecasted growth. Neither index is an investment product available for purchase.

Mutual Funds involve risk including the possible loss of principal. The fund can invest in smaller-sized companies which may experience higher failure rates than larger companies and they normally have a lower trading volume than larger companies. The Fund's ethical values screening criteria could cause it to underperform similar funds that do not have such screening criteria. The fund can have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. The fund can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards. The fund can have risk associated with a higher portfolio turnover which could result in higher transactional costs.







Fund Contact:
Robin John
877-771-EVEN (3836), x55

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  Majority of Canadians Plan to Open Their Wallets on Boxing Day in 2012 Biopharm Asia Announces Approval of 15c2-11 Filing and Anticipates OTCBB Listing
Bereitgestellt von Benutzer: MARKETWIRE
Datum: 18.12.2012 - 14:00 Uhr
Sprache: Deutsch
News-ID 213820
Anzahl Zeichen: 0

contact information:
Town:

BOSTON, MA



Kategorie:

Commercial & Investment Banking



Diese Pressemitteilung wurde bisher 214 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Eventide Gilead Fund Ranked #1 Midcap Growth Fund by Lipper and the Wall Street Journal for the One-Year Period Ending November 30, 2012"
steht unter der journalistisch-redaktionellen Verantwortung von

Eventide Gilead Fund (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Eventide Launches the Eventide Multi-Asset Income Fund ...

BOSTON, MA -- (Marketwired) -- 07/16/15 -- Eventide is pleased to announce the launch of their third mutual fund, the Eventide Multi-Asset Income Fund. The Multi-Asset Income Fund seeks current income while maintaining the potential for capital appr ...

Alle Meldungen von Eventide Gilead Fund



 

Werbung



Facebook

Sponsoren

foodir.org The food directory für Deutschland
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z